Is deuterated coxitinib effective?

Deucravacitinib (Deucravacitinib), as an oral small molecule inhibitor, has indeed shown significant results in the treatment of moderate to severe plaque psoriasis.

Multiple clinical trials, includingPEOTYK PSO-1 and PEOTYK PSO-2, have confirmed the efficacy of deuterated colexitinib in patients with moderate to severe plaque psoriasis. These trials showed that patients treated with decolexitinib achieved PASI 75 (an improvement in Psoriasis Area and Severity Index score of at least 75%) and PGA at week 16 compared with placebo. The proportion of 0/1 (static doctor's overall assessment score of 0 or 1, indicating that the skin lesions are cleared or basically cleared) increased significantly. For example, in the PEOTYK PSO-1 and PEOTYK PSO-2 studies, the PASI in the Deucravacitinib group at 16weeks 75Response rates were 58% and similarly high rates, respectively, compared with 13%and lower rates in the placebo group.

Deuterated colexitinib is not only effective in systemic skin lesions, but also shows good efficacy in psoriatic skin lesions in difficult-to-treat areas such as scalp, palms and soles, and nails. For example, data show that at 16 weeks of treatment, nearly 63% of patients with moderate to severe scalp psoriasis treated with deuterated colexitinib achieved a state of clearing or almost clearing of scalp lesions.

Long-term study data further confirms the sustainability of the efficacy of deuterated colexitinib. For example, the POETYK PSO long-term extension trial showed that after three years of continuous treatment with deuterated colexitinib, the PASI 75 response rate remained at a high level (e.g. 73.2%), and the safety characteristics are consistent with the past, without increasing the incidence of adverse or serious adverse events.